sur Biophytis (EPA:ALBPS)
Biophytis to Attend BIO-Europe Spring 2025 in Milan
Biophytis, a clinical-stage biotech company, is set to participate in the BIO-Europe Spring 2025 event in Milan from March 17 to 19. The company, known for developing treatments for age-related diseases, aims to exchange insights with industry leaders on its leading drug candidate, BIO101. This compound is being developed for conditions such as obesity and sarcopenia, with various phases of trials underway.
During the event, Edouard Bieth, Chief Business Officer of Biophytis, will be engaging in numerous meetings. The conference is a major European gathering for pharmaceutical professionals, providing a platform for networking and discussion on innovative solutions in biotechnology.
The company's presence highlights its commitment to advancing research and collaboration within the industry. Biophytis operates globally, with key locations in France, the USA, and Brazil.
R. E.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Biophytis